AccuStem Q2 FY26 net loss narrows 37% to $252,573
ACUT•AccuStem reports narrower Q2 FY26 loss
- AccuStem posted a net loss of USD 252,573 for the quarter ended June 30, 2026, narrowing 37% year over year.
- Other income turned positive to USD 98,400, due to one-off supplier invoice credits deemed no longer due and payable.
- Research and development expense fell 27% to USD 43,712, primarily on timing of technology-transfer spending.
- General and administrative costs declined 10% to USD 307,261, mainly due to no payroll-related bonus costs in 2026.
- Cash and cash equivalents totaled USD 12,928 at June 30, 2026; existing cash is expected to fund operations until August 2026.
Related News
Bally's Q2 revenue slightly beats estimates on growth in Intralot B2C, North America Interactive
BALY•
Antiaging Quantum Living FY27 Q1 net loss widens 138.81% to $318,509; revenue more than doubled to $730,117
AAQL•
